Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

FDA issues Complete Response Letter to AcelRx Pharmaceuticals for Zalviso System for Acute and Breakthrough Pain


AcelRx Pharmaceuticals, Inc. has ...

FDA approves Targiniq ER an opioid analgesic for treatment of Severe Pain-Purdue Pharma


The FDA has approved Targiniq ER ...

CHMP recommends Zydelig for treatment of CLL and Follicular Lymphoma- Gilead Sciences.


Gilead Sciences, Inc. announced ...

CHMP recommends IDegLira (now Xultophy) for treatment of Type 2 Diabetes - Novo Nordisk


Novo Nordisk announced that the ...

Zerenex meets endpoints in PERFECTED study for treatment of Hyperphosphatemia- Keryx Biopharma


Keryx Biopharmaceuticals, Inc. ...

Merck Inc, cuts sales jobs in US


Merck Inc in the US is eliminating 600 ...

CHMP recommends extended indication for Ozurdex for DME- Allergan


Allergan, Inc. has announced that ...

Recent Updates


Clinical Guidelines

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Guidelines for the Management of Strabismus in Childhood

Prophylaxis against infective endocarditis - Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures

Common mental health disorders: Identification and pathways to care

Medical Journals

Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes

Association of STAT4 gene polymorphism with increased susceptibility of rheumatoid arthritis in a northern Chinese Han subpopulation

Effects of a Chinese Herbal Medicine, Guan-Jen-Huang (Aeginetia indica Linn.), on Renal Cancer Cell Growth and Metastasis.

Open Conversion After Endovascular Aortic Aneurysm Repair: A Single-Center Experience

epgonline.org Social